Highlights Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 16:55:00 10/04/2026 BST			5-day change	1st Jan Change
80.19 ^EUR	-0.90%		-2.89%	-3.06%

04-10	SANOFI : JP Morgan is Neutral	ZD
04-10	SANOFI : UBS reaffirms its Neutral rating	ZD

Highlights

04-09	Sanofi's Covid-19 vaccine Nuvaxovid authorised in Canada	RE
04-09	Sanofi Becomes Market Authorization Holder for Nuvaxovid in Canada	CI
04-08	AlphaValue/Baader Europe Lowers Target Price, Estimates for Sanofi Amid R&D Setbacks	MT
04-07	Sanofi Announces Lunsekimig Meets Primary And Key Secondary Endpoints In Phase 2 Respiratory Studies In Asthma And CRSwNP	CI
03-31	Adragos Pharma GmbH backed by FSN Capital VI acquired Sterile Fill-finish facility in Maisons-Alfort, France from Sanofi.	CI
03-31	EU Conditionally Approves Sanofi's Chronic Graft-vs-Host Disease Treatment	MT
03-31	Sanofi Secures EU Conditional Marketing Approval for Graft-vs-Host Disease Medicine	MT
03-31	Sanofi Announces EU Approval of Rezurock for Treatment of Chronic Graft-Versus-Host Disease	CI
03-30	European markets cautious as conflict drags on
03-30	Atos, Dékuple, VusionGroup... stocks to watch today in Paris
03-28	Sanofi Presents New Results from Amlitelimab Phase 3 Studies in Atopic Dermatitis	CI
03-27	Colgate must face lawsuits over safety of mouth rinse for young children	RE
03-27	European Stocks Falling in Friday Trading as Investors Remain Jittery Over Middle East Conflict, Rising Oil Prices	MT
03-27	EU Medicines Agency Panel Backs Subcutaneous Version of Sanofi's Blood Cancer Drug	MT
03-27	EU regulator backs Sanofi's injectable version of blood cancer drug	RE
03-27	Sanofi Says Subcutaneous Form of Sarclisa for Multiple Myeloma Wins EU Panel Support	MT
03-27	Sanofi's Sarclisa subcutaneous formulation via on-body injector recommended for EU approval	RE
03-27	Sanofi?s Sarclisa Subcutaneous Formulation Administered Via On-Body Injector is Recommended for EU Approval by the CHMP to Treat Multiple Myeloma	CI
03-27	AstraZeneca drug reduces flare-ups of chronic lung disease in late-stage trials	RE
03-26	Jefferies views Sanofi as the cheapest large-cap pharma stock
03-26	Arecor Therapeutics Receives $0.5 Million Milestone Payment from Ligand Pharmaceuticals	CI
03-25	Thermo Fisher Scientific and SHL Medical Collaborate to Deliver Fully Integrated Drug-Device Solutions	CI
03-24	Regeneron Pharmaceuticals, Inc. and Sanofi Approve Dupixent for Treatment of Adults with Bullous Pemphigoid in Japan	CI
03-24	Japan Clears Sanofi, Regeneron's Dupixent as First Targeted Therapy for Rare Skin Disease	MT
03-24	Sanofi releases its "analyst memo"